Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Metabolic Disorder Therapeutics Market, By Disease
7.1. Metabolic Disorder Therapeutics Market, By Disease, 2021-2028
7.1.1. Lysosomal Storage Diseases
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Diabetes
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Obesity
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Inherited Metabolic Disorders
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Hypercholesterolemia
7.1.5.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Metabolic Disorder Therapeutics Market, By Therapy Type
8.1. Metabolic Disorder Therapeutics Market, By Therapy Type, 2021-2028
8.1.1. Enzyme Replacement Therapy
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Cellular Transplantation
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Small Molecule Based Therapy
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Substrate Reduction Therapy
8.1.4.1. Market Revenue and Forecast (2016-2028)
8.1.5. Gene Therapy
8.1.5.1. Market Revenue and Forecast (2016-2028)
8.1.6. Drug Therapy
8.1.6.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Metabolic Disorder Therapeutics Market, By Route of Administration
9.1. Metabolic Disorder Therapeutics Market, By Route of Administration, 2021-2028
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Parenteral
9.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Metabolic Disorder Therapeutics Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Disease (2016-2028)
10.1.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.1.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.1.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.1.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.1.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.1.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Disease (2016-2028)
10.2.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.2.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.2.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.2.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.2.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.2.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Disease (2016-2028)
10.2.6.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.2.6.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Disease (2016-2028)
10.2.7.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.2.7.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Disease (2016-2028)
10.3.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.3.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.3.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.3.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.3.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.3.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Disease (2016-2028)
10.3.6.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.3.6.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Disease (2016-2028)
10.3.7.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.3.7.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.4.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.4.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.4.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.4.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Disease (2016-2028)
10.4.6.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.4.6.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Disease (2016-2028)
10.4.7.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.4.7.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Disease (2016-2028)
10.5.4.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.5.4.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Disease (2016-2028)
10.5.5.2. Market Revenue and Forecast, By Therapy Type (2016-2028)
10.5.5.3. Market Revenue and Forecast, By Route of Administration (2016-2028)
Chapter 11. Company Profiles
11.1. Novo Nordisk A/S
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Sanofi S.A.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Boehringer Ingelheim GmbH
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Merck KgaA; Amgen, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AstraZeneca PLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Actelion Pharmaceuticals Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Shire PLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. AbbVie, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Biocon Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. BioMarin Pharmaceutical, Inc.
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Bristol-Myers Squibb Company.
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Cipla, Inc.
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. CymaBay Therapeutics, Inc
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms